IMI - Institute for Medical Immunology
About Us
Research
Publications
Training
News
July to December 2010
Programme des conférences de l'Académie Royale de Médecine de Belgique
December 22 - IXème réunion du Groupe de Contact FNRS, Brussels
December 21 - Common seminar IBMM-IMI with Pierre Smeesters, ULB, Charleroi
December 15-18 - Annual congress of the Société Francophone de Transplantation, Geneva
December 15 - Pharma Connexion, Gembloux
December 7 - Seminar with Lionel Poulin, Cancer Research UK, London, United Kingdom
November 30 - Seminar with Arnaud Goolaerts, Université Paris 7, INSERM U773, Paris
November 26 - Annual BIS meeting, Brussels
November 23 - Biopark formation sur la microscopie optique, Gosselies
November 16 - Seminar with Basile Stamatopoulos, Institut Bordet, Hématologie Expérimentale, Brussels
November 9 - Programme d'excellence CIBLES : rencontre scientifique, Gosselies
November 4-5 - Annual meeting of the Argentinean Society of Immunology, Buenos Aires
October 26 - Common seminar IBMM-IMI with Thomas Brocker, Ludwig-Maximilians-Universität,Munich, Germany
October 19 - Seminar with Sofia Buonocore, GlaxoSmithKline Biologicals, Rixensart, Belgium
October 12 - Seminar with Laure Ysebrant de Lendonck
October 5 - Seminar with M. Najar and G. Raicevic, Institut Bordet, Brussels
September 28 - Seminar with Andrea Knight, University College London Medical School, London, United Kingdom
September 26-30 - 11th International Symposium on Dendritic Cells, Lugano
September 21 - Common seminar IBMM-IMI with Patrick Collombat, Université de Nice, INSERM U636, Nice, France
September 20 - Late summer school
September 15-19 - Transplantation Society Meeting, Vancouver

October 5 - Seminar with M. Najar and G. Raicevic, Institut Bordet, Brussels

Tuesday October 5, 2010 from 12.00 to 13.00
M. Najar and G. Raicevic, Institut Bordet, Brussels

"Mesenchymal stromal cells (MSC) and their potential as immunomodulators"

MSC are multipotent cells that can be isolated from several human tissues and expanded ex vivo for clinical use. MSC are identified by their adherent properties, immunophenotype and differentiation potential. They are able to modulate the function of all major immune cell populations, either direcly or through soluble factors. MSC also regulate and maintain T-regulatory phenotype. The immunosuppressive potential of MSC is not constitutive but induced under specific circumstances (T cell cytokines, inflammation…). MSC express Toll like receptors (TLR) and are activated by TLR ligands leading to modulation of the MSC functions (migration, differentiation, immunosuppression capacities) especially in an inflammatory context. The immunomodulatory effects, the molecular mechanisms implicated, TLR expression and the responses to TLR challenging vary greatly between MSC sources : bone marrow, adipose tissue and umbilical cord. The biological behavior of MSC obtained from different sources and in different situations (inflammation, infection,…) is important to establish with respect to the safety and efficacy of MSC-based cell-therapies.

 

> Search
Latest news
- February 15 : Biopark seminar with Susan Gasser> Read More
- February 28 : Bioké formation on flow cytometry> Read More
Recent publication in Leukemia> Read More
Recent publication in Nat Immunol> Read More
Recent publication in Hepatology> Read More
Recent publication in J Immunol> Read More
Recent publication in Am J Transplant> Read More
> Complete List of Seminars
> Upcoming Meetings and Events
> Full News Archives
Interesting Links
CMMI Center for Microscopy and Molecular Imaging

BioPark

BioWin Pôle de Compétitivité Santé de Wallon e
IBMM Institut de Biologie et de Médecine Moléculaires


GIGA Groupe Interdisciplinaire de Génoprotéomique Appliquée
Immunehealth provides Services to Biotech Companies and Biopharma in the field of Immunology    

 





Designed by Styrion-Kheper | Intuitive Extranet